Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Tesla Fixed Tech100 Index (KTSLT100)
6/4/2026, 12:00:00 AM
Announced on 2026-06-04 that the U.S. FDA granted Breakthrough Therapy Designation for salanersen. A Medium importance is estimated as this designation significantly accelerates the regulatory path for a key asset, estimated.
Korean Translation
2026년 6월 4일, 미국 FDA가 척수성 근위축증(SMA) 치료제 살라너센에 대해 혁신치료제 지정을 승인했다고 발표함. 혁신치료제 지정의 규제적 이점을 고려하여 중요도를 'Medium'으로 예상함.
Related Recent Events
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is scheduled to announce its Q2 2026 earnings results on August 5, 2026 expected. Medium importance estimated as earnings releases typically cause >5% price volatility.
8/5/2026, 12:00:00 AM
Teradyne Inc (TER) · Earnings Release
High importance is estimated as earnings reports typically drive significant volatility; Q2 2026 earnings release with revenue guidance of $1.15B-$1.25B and non-GAAP EPS of $1.86-$2.15 is scheduled.
8/4/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Earnings Release
Market impact is estimated at Medium (>=5%) based on historical earnings volatility; Axon's Q2 2026 earnings report is scheduled.
8/3/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Amazon.com Inc (AMZN) · Earnings Release
Amazon's Q2 2026 earnings release is expected on July 30, 2026. The company guided for net sales between $194.0 billion and $199.0 billion. Low importance is assigned as the market reaction has not yet occurred expected.
7/30/2026, 12:00:00 AM